LABORATORY CORP OF AMERICA HOLDINGS Insider Trading for April 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LABORATORY CORP OF AMERICA HOLDINGS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LABORATORY CORP OF AMERICA HOLDINGS for April 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 07 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 1,010 | 0 | 9,608 | |
| Apr 07 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 113.31 | 372 | 42,151 | 8,087 | 8.5 K to 8.1 K (-4.40 %) |
| Apr 07 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 1,010 | 0 | 8,459 | 7.4 K to 8.5 K (+13.56 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 131.95 | 24,583 | 3,243,727 | 343,804 | 368.4 K to 343.8 K (-6.67 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 131.95 | 24,583 | 3,243,727 | 343,804 | 368.4 K to 343.8 K (-6.67 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Grant | A | 0.00 | 54,995 | 0 | 368,387 | 313.4 K to 368.4 K (+17.55 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Grant | A | 0.00 | 54,995 | 0 | 368,387 | 313.4 K to 368.4 K (+17.55 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Payment of Exercise | F | 131.95 | 1,106 | 145,937 | 5,351 | 6.5 K to 5.4 K (-17.13 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Grant | A | 0.00 | 3,721 | 0 | 6,457 | 2.7 K to 6.5 K (+136.00 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 131.95 | 5,787 | 763,595 | 26,124 | 31.9 K to 26.1 K (-18.13 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Grant | A | 0.00 | 12,945 | 0 | 31,911 | 19 K to 31.9 K (+68.25 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 131.95 | 1,014 | 133,797 | 7,449 | 8.5 K to 7.4 K (-11.98 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Grant | A | 0.00 | 3,402 | 0 | 8,463 | 5.1 K to 8.5 K (+67.22 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 131.95 | 1,153 | 152,138 | 3,213 | 4.4 K to 3.2 K (-26.41 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Grant | A | 0.00 | 3,880 | 0 | 4,366 | 486 to 4.4 K (+798.35 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 131.95 | 1,695 | 223,655 | 10,543 | 12.2 K to 10.5 K (-13.85 %) |
| Apr 01 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Grant | A | 0.00 | 3,880 | 0 | 12,238 | 8.4 K to 12.2 K (+46.42 %) |